Melanotan I vs Melanotan II

What Are Melanotan I and Melanotan II?

Melanotan I (Afamelanotide) is a Melanocortin-1 receptor (MC1R) agonist. Synthetic α-MSH analog developed to stimulate melanin production through selective MC1R activation. It is researched for skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning.

Melanotan II (Melanotan II (cyclic α-MSH analog)) is a Non-selective melanocortin receptor agonist. Synthetic cyclic α-MSH analog with non-selective activity across MC1, MC3, MC4, and MC5 receptors. It is researched for rapid skin darkening, appetite suppression, erectile function enhancement, increased libido.

While both are popular research peptides, they work through fundamentally different mechanisms and serve different primary purposes.

How Do Melanotan I and Melanotan II Work Differently?

Melanotan I mechanism: Selectively binds MC1R on melanocytes, triggering the cAMP-dependent signaling cascade that increases MITF transcription factor activity. This upregulates tyrosinase enzyme expression and melanin synthesis, producing skin darkening without requiring UV exposure.

Melanotan II mechanism: Non-selectively activates multiple melanocortin receptors simultaneously: MC1R drives melanin synthesis in skin, MC3R/MC4R affect appetite suppression and sexual function, MC5R modulates exocrine glands. This broad receptor activation produces rapid tanning but also unpredictable systemic effects including libido enhancement and appetite suppression.

These distinct mechanisms are why the two peptides are often used for different research goals — or combined to target multiple pathways.

How Do the Dosing Protocols Compare?

Melanotan I: 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) administered every 60 days (implant) or daily (injection) via subcutaneous implant (approved) or subcutaneous injection. Half-life: ~2 hours circulating; implant provides 2-month depot release. Cycle: 60-day implant cycles; 4-8 weeks injection cycles.

Melanotan II: 250-500 mcg per injection administered every other day via subcutaneous injection. Half-life: not precisely established; effects persist longer than MT-I. Cycle: 2-4 weeks for tanning effects.

Use our peptide calculator for reconstitution math for either compound.

How Do the Benefits Compare?

Melanotan I benefits: skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning.

Melanotan II benefits: rapid skin darkening, appetite suppression, erectile function enhancement, increased libido.

The overlap in benefits determines whether these peptides compete for the same use case or complement each other in a stack.

How Do the Side Effects Compare?

Melanotan I: Milder than Melanotan II: fatigue, headache, facial flushing, nausea, development or darkening of freckles/moles. Slower onset than MT-II (weeks vs days). Generally considered safer.

Melanotan II: Extensive adverse effects: nausea, vomiting, facial flushing, involuntary erections, yawning, loss of appetite. Serious reports of rhabdomyolysis, renal infarction, posterior reversible encephalopathy syndrome, and sympathomimetic toxicity. Increased melanoma risk, atypical moles, melanonychia (nail darkening). Dose-dependent toxicity.

Can You Stack Melanotan I and Melanotan II Together?

Many researchers combine Melanotan I and Melanotan II in stacking protocols. The different mechanisms mean they can potentially provide complementary effects without competing for the same receptors.

Used as standalone; not typically combined with other melanocortin peptides. See our stacking guide for general principles.

Which Is Better: Melanotan I or Melanotan II?

There is no universal answer. Melanotan I may be preferable for researchers focused on skin pigmentation, while Melanotan II is stronger for rapid skin darkening.

For the most comprehensive results, many researchers combine both. Review each compound's individual guide for detailed protocols: Melanotan I | Melanotan II.

Frequently Asked Questions